Sanofi-Aventis Details Plans for Emerging Markets
This article was originally published in PharmAsia News
As Big Pharma strives to educate Wall Street on the promise of emerging markets, Sanofi-Aventis has come out swinging: in a statistic-filled July 2 analyst forum, top executives noted they have a bigger market share and more experience than rivals in some of the fastest-growing countries
You may also be interested in...
SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June
Sanofi’s recent acquisition of Medley, Brazil’s leading generics manufacturer, reflects its strategy of going local — and generic — in emerging markets.
SHANGHAI - China's State Council has approved a three-year plan to implement part of the country's sweeping health system reforms, and plans to invest RMB 850 billion ($124 billion) into the sector by 2011, according to a report published on the Chinese government's official Web site